The Union Health Ministry has clarified that none of the tested cough syrup samples in India contained harmful chemicals like diethylene glycol or ethylene glycol, both of which are known to cause serious kidney injury. The statement comes amid rising concerns over cough syrup safety following reports of contaminated batches in other countries.

Centre's Assurance on Cough Syrup Safety

The Union Health Ministry has conducted extensive tests on domestically manufactured cough syrups. The findings confirm that all tested samples are free from diethylene glycol and ethylene glycol, chemicals that can pose severe health risks including kidney failure.

Ministry officials stated that the results are part of ongoing drug safety monitoring and reiterated that there is no evidence of contamination in Indian cough syrups available in the market. Public health experts have welcomed the announcement, noting that it should reassure consumers and reduce panic over cough syrup consumption.

Tamil Nadu Flags Coldrif Batch

Contrastingly, the Tamil Nadu health authorities reported that tests on the Coldrif cough syrup batch revealed the presence of diethylene glycol. In response, the state government ordered an immediate halt to production of the batch and advised strict monitoring of manufacturing units.

Officials highlighted that the detection was part of routine quality control checks under the Drugs and Cosmetics Act. The authorities are investigating the source of contamination and have asked manufacturers to ensure compliance with safety and quality standards.

Implications for Public Health

The contrasting reports from the Centre and Tamil Nadu underline the importance of continuous testing and vigilance in pharmaceutical production. While the Union Health Ministry's nationwide tests assure the public of general safety, state-level alerts like the Coldrif batch detection highlight potential localized quality issues.

Health experts recommend consumers check batch numbers and expiry dates before purchasing cough syrups and follow official advisories. Authorities have also emphasized the need for strict adherence to Good Manufacturing Practices (GMP) to prevent adulteration.

Government Action and Monitoring

The Ministry of Health has called for heightened surveillance and stricter inspection protocols for cough syrup manufacturers. Manufacturers have been advised to maintain comprehensive documentation of raw materials, production processes, and quality checks to ensure public safety.

Meanwhile, Tamil Nadu authorities are coordinating with central drug regulatory bodies to trace the source of contamination in the Coldrif batch and prevent recurrence. Regular testing, swift reporting, and transparency in communication are expected to minimise health risks for consumers.

Public Advisory

The government has reiterated that consumers should not panic, as the majority of cough syrup brands are safe. It is advised to follow medical prescriptions, avoid unverified brands, and report any adverse effects to local health authorities.

The alert regarding the Coldrif batch serves as a reminder of the critical role of state-level monitoring and the need for manufacturers to comply with strict safety regulations. Combined efforts by the Union Health Ministry and state authorities aim to maintain the highest standards of drug safety in India.

Conclusion

The current situation reflects a balanced approach to public health. While the Union Health Ministry ensures nationwide safety of cough syrups, state-level vigilance like Tamil Nadu’s Coldrif alert protects consumers from potentially harmful batches.

Authorities are expected to continue regular inspections and testing, ensuring that all cough syrups in the Indian market remain safe for consumption. Consumers are encouraged to stay informed through official updates and follow medical advice while purchasing or using cough syrups.

The ongoing collaboration between central and state health authorities reinforces India's commitment to drug safety, public health protection, and quality assurance in pharmaceuticals.

Join our Telegram Channel for Latest News and Regular Updates.

Start your Mutual Fund Journey  by Opening Free Account in Asset Plus.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.